Q-omics provides the consensus-scored GUCA1B profile across patient tissues and cancer cell-line models. GUCA1B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GUCA1B is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, GUCA1B RNA expression shows 18,234 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, THCA, and THYM as cancer lineages where GUCA1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GUCA1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GUCA1B survival associations across molecular data types. GUCA1B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GUCA1B RNA expression–survival associations across cancer types. High GUCA1B expression shows unfavorable associations in KIRC, KIRP and ACC, but favorable associations in HNSC, UCS and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for GUCA1B RNA expression.
This table summarizes GUCA1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GUCA1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GUCA1B shows lower tumor expression in THCA, UCEC, BRCA and BLCA and higher tumor expression in KIRC and STAD. The THCA box plot shows higher GUCA1B RNA expression in normal versus tumor tissue (log2 FC = −0.655, t-test p < 0.001).
This table shows molecular features associated with GUCA1B in patient tissues and cancer cell lines. In patient samples, GUCA1B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GUCA1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
